Johnson & Johnson’s Board of Directors has approved a cash dividend of $1.30 per share for the first quarter of 2026. The dividend will be paid on March 10, 2026 to shareholders of record at the close of business on February 24, 2026, with an ex-dividend date of February 24, 2026. This marks the company’s 61st consecutive year of dividend increases, reflecting its commitment to returning capital to investors and its confidence in sustained free cash flow generation across its pharmaceuticals, medical devices and consumer health segments.

In its latest SEC filing for the third quarter, Ascent Group LLC reduced its stake in Johnson & Johnson by 8.3%, selling 5,723 shares to end the period with 63,449 shares valued at approximately $11.8 million. The move contrasts with several other institutions that either initiated positions or increased holdings; for example, Evolution Wealth Management and Clayton Financial Group each opened stakes during the period, while Semmax Financial Advisors upped its position by 55%. Overall, institutional investors and hedge funds continue to hold a significant majority of the company’s outstanding shares, accounting for roughly 69.6% of the total.